The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

The Centers for Medicare and Medicaid Services has named 33 states, as well as Washington, D.C., and Puerto Rico, as participants in its Cell and Gene Therapy Access Model, which is designed to treat ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

"The Cell and Gene Therapy Access Model will increase access to promising therapies that improve the chances of people living longer, healthier lives," CMS Administrator Chiquita Brooks-LaSure ...

The agency will strike agreements with sickle cell gene therapy manufacturers via the Cell and Gene Therapy Access Model, which it unveiled last February.

Together, this proposal and the CGT Access Model—scheduled to roll out in early 2025—herald the beginning of what, finally, may be a practical reimbursement strategy for ultra-expensive cell ...

Key Takeaways: On January 30, 2024, the Center for Medicare and Medicaid Innovation (CMMI) issued additional details regarding the forthcoming Cell and Gene Therapy (CGT) Access Model, which was ...

The funding provided close to $1 million to support the creation of a new Cell and Gene Therapy Technology, Engineering, Analytics, Manufacturing, & Science academic program, known as CGT-TEAMS, that ...